Cutler Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Cutler Group’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13	Closed	-$2K	–	5671
2022 Q2	$2K	Hold	13	–	–	﹤0.01%	4416
2022 Q1	$6K	Hold	13	–	–	﹤0.01%	4064
2021 Q4	$34K	Sell	13 -20	-61%	-$154K	﹤0.01%	2711
2021 Q3	$51K	Buy	+33	New	+$284K	﹤0.01%	2498
2021 Q2	–	Sell	-1	Closed	-$1K	–	6527
2021 Q1	$1K	Buy	+1	New	+$11.7K	﹤0.01%	5435

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's SEEL Position: Q4 2023 in Review

Cutler Group held its Seelos Therapeutics, Inc. Common Stock (SEEL) position steady in Q4 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4515.

Cutler Group first reported a position in SEEL in Q1 2021 and has held it in 4 quarters since. The position peaked at $29K in Q1 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Cutler Group held 0 shares of Seelos Therapeutics, Inc. Common Stock worth $0 as of Q4 2023.
Cutler Group left its Seelos Therapeutics, Inc. Common Stock share count unchanged in Q4 2023.
Seelos Therapeutics, Inc. Common Stock made up ﹤0.01% of Cutler Group's portfolio in Q4 2023, its #4515 holding.
Cutler Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 4 quarters since.
Cutler Group's Seelos Therapeutics, Inc. Common Stock position peaked at $29K in Q1 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.